19

Aug2022
On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More

20

Jul2022
On June 30, 2022, PMPRB issued a Notice and Comment which published its Proposed Interim Guidance and invited stakeholder comments until July 18, 2022. This Interim Guidance outlines PMPRB’s intentions for regulating the prices of patented medicines in the “interim period” between the coming-into-force date ... Read More

28

Jun2022
François-Xavier has joined PDCI Market Access as a Senior Health Economist. He is responsible for leading the conception and development of strategic, evidence-based economic components for submission to Canadian Health Technology Assessment (HTA) bodies and public/private payers. Among other roles, he ensures that PDCI is ... Read More

20

Jun2022
Ottawa, June 20, 2022: PDCI study finds Canada Ranks 10th on its Attractiveness for New Medicine Launch Launched today by PDCI Market Access, a new study finds Canada ranks 10th out of 14 countries on its attractiveness for ... Read More

20

May2022
PDCI is excited to announce the launch of its new Webinar Series, kicking-off next month with the release of PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch?During this calendar year, PDCI will host quarterly, lunchtime educational webinars, covering issues of interest to ... Read More

05

May2022
On May 3, 2022, CADTH announced the mandate expansion of the Scientific Advice Program to include advice on RWE generation plans after protocols for pivotal trials are finalized. What to know: The expanded program will run for a 1-year learning ... Read More

25

Apr2022
On April 14, 2022, Health Canada announced that the government will:  Proceed only with the proposed amendments to the Regulations pertaining to schedule of reference countries (the PMPRB11 replacing the PMPRB7).   Not proceed with new excessive price factors (cost effectiveness, market size, GDP) nor the reporting of third-party ... Read More

04

Apr2022
On March 31, 2022, PMPRB published its 2020 Annual Report on its website. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine investment and launch since drug pricing reform began in 2017. Statistical Highlights201820192020Total # of Patented Medicines for Human Use Reported ... Read More

25

Mar2022
On September 29, 2021, the Attorney General of Canada applied for leave to appeal to the Supreme Court of Canada concerning the Federal Court of Appeal’s (FCA) July 2021 decision in Alexion Pharmaceuticals Inc v Canada (Attorney General). On March 24, 2022, the Supreme Court of Canada ... Read More

23

Feb2022
PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. Volume 2, Issue 2 AnalyticsOur analytics article features ... Read More